Delaunay M M, Amici J M, Avril M F, Avril A, Barrut D, Blanc L, Blondet R, Bonichon E, Carolus J M, Depadt G
Unité de Dermato-Cancérologie, Centre Hospitalier et Fondation Bergonié, Bordeaux.
Ann Dermatol Venereol. 1991;118(4):287-95.
Lung metastases from malignant melanoma are frequent and they often inaugurate the metastatic stage. Exceptionally, they present as one or a few nodules, and in the absence of any other secondary lesion these cases raise the problem of surgical eradication. A retrospective multicentre study was carried out in a series of 38 patients and its results were compared to the data obtained from a review of 435 published cases in order to assess the value of surgery in terms of survival and to delimit its indications as closely as possible. Our series of 38 patients comprised 20 men and 18 women aged from 22 to 93 years (mean 51 years, median 55 years). The primary tumour was located in the trunk in 47 p. 100 of the cases; it was nodular in 33 p. 100 and superficial but extensive in 37.5 p. 100. The time elapsed before the metastases appeared varied from 0 to 108 months (median 40 months). Surgery had been radical in 70 p. 100 of the patients and usually limited, tumorectomies and segmentectomies accounting for 51 p. 100 of the operations. RESULTS. In this series the duration of survival varied between 2 and 144 months (mean 26 months, median close to 15 months), with a 20 p. 100 probability of survival at 5 years (fig. 1). Disease free survival varied from 0 to 144 months (mean 22.5 months, median 10.5 months) (fig. 2, curve 1). The parameters of response as regards patients, primary tumour, metastases and treatment were analysed. Response was uninfluenced by sex and slightly influenced by age, with a difference of borderline significance between subjects under and over 50. The primary tumour characteristics did not affect survival, and the features of metastases were of extremely varied importance. The number of operable metastases was not determinant. On the other hand, the presence of mediastinal lesions, either isolated or associated with lung lesions, worsened the prognosis of terms of survival and much more significantly so in terms of remission (fig. 3 and 4). The evaluation of evolutive characteristics, such as date of appearance and tumour doubling time, was inconclusive. Survival was of the same duration after wide and limited surgery, so that tumorectomy or segmentectomy should preferably be performed. The results of surgical treatment were determinant, with a highly significant difference in survival between radical and incomplete surgery (fig. 5 and fig. 2, curve 2). DISCUSSION. The median survival of patients operated upon for lung metastases is diversely evaluated in the literature as 8 to 29 months (table V), the mean figure of 16 months being virtually the same as that of our series. In this, as in most of the previously published series, the maximum duration of survival was beyond 8 to 10 years. The mean survival rate at 5 years is very close to the one we have recorded (20 p. 100) (table V). Compared with other treatments of lung metastases, surgery may be considered as capable of prolonging survival by 6 months; this is not much unless we add the possibility of a 5-year survival in 1 out of 5 operated patients and the possibility of a survival exceeding 8 or 10 years in 2 to 5 p. 100 of the cases. Some prognostic factors seem to constitute positive or negative criteria of operability. This is the case with mediastinal lesions which may consist of a metastasis of metastasis or of a lymph node invasion associated or not with the lung lesion, but in any case correspond to the involvement of more than one site. Mediastinal lesions must be systematically looked for and treated as contraindications of surgery, as shown by the differences in survival recorded in our series. Opinions differ as regards the value of evolutive parameters of the metastasis. For some authors, a more than 5 years interval before the metastasis appears is associated with a good chance of prolonged survival, whereas a less than 6 months or 1 year interval reflects a steadily high progressiveness and in practice precludes surgery. The value of the
恶性黑色素瘤的肺转移很常见,且常常标志着转移阶段的开始。极少数情况下,肺转移表现为一个或几个结节,在没有任何其他继发性病变的情况下,这些病例引发了手术根除的问题。我们对38例患者进行了一项回顾性多中心研究,并将其结果与从435例已发表病例的综述中获得的数据进行比较,以便评估手术在生存方面的价值,并尽可能精确地界定其适应症。我们的38例患者系列中,包括20名男性和18名女性,年龄在22岁至93岁之间(平均51岁,中位数55岁)。47%的病例原发肿瘤位于躯干;33%为结节状,37.5%为浅表但范围广泛。转移出现前经过的时间从0至108个月不等(中位数40个月)。70%的患者手术为根治性,通常为局限性手术,肿瘤切除术和节段切除术占手术的51%。结果。在该系列中,生存时间在2至144个月之间(平均26个月,中位数接近15个月),5年生存率为20%(图1)。无病生存期从0至144个月不等(平均22.5个月,中位数10.5个月)(图2,曲线1)。分析了关于患者、原发肿瘤、转移灶和治疗的反应参数。反应不受性别影响,受年龄影响较小,50岁以下和50岁以上受试者之间的差异具有临界显著性。原发肿瘤特征不影响生存,转移灶的特征重要性差异极大。可手术转移灶的数量不是决定性因素。另一方面,纵隔病变的存在,无论是孤立的还是与肺部病变相关的,都会使生存预后恶化,在缓解方面更显著(图3和图4)。对诸如出现日期和肿瘤倍增时间等演变特征的评估尚无定论。广泛手术和局限性手术后的生存时间相同,因此最好进行肿瘤切除术或节段切除术。手术治疗结果是决定性的,根治性手术和不完全手术在生存方面有极显著差异(图5和图2,曲线2)。讨论。文献中对接受肺转移手术患者的中位生存期评估各不相同,为8至29个月(表V),平均数字16个月与我们系列中的几乎相同。在本研究以及大多数先前发表的系列中,最长生存时间超过8至10年。5年平均生存率与我们记录的非常接近(20%)(表V)。与肺转移的其他治疗方法相比,手术可被认为能够将生存期延长6个月;除非我们加上5名手术患者中有1名有5年生存的可能性以及2%至5%的病例有超过8年或10年生存的可能性,否则这增加得并不多。一些预后因素似乎构成了可手术性的阳性或阴性标准。纵隔病变就是这种情况,它可能由转移灶或与肺部病变相关或不相关的淋巴结侵犯组成,但无论如何都对应于多个部位的受累。纵隔病变必须系统地查找并作为手术禁忌症进行处理,正如我们系列中记录的生存差异所示。关于转移灶演变参数的价值存在不同意见。对于一些作者来说,转移出现前超过5年的间隔与延长生存的良好机会相关,而间隔少于6个月或1年则反映出稳定的高进展性,实际上排除了手术。